Asnani et al., 2020 [292], in a prospective study, revealed that HER2-positive breast cancer patients, who experienced CTRCD presented with statistically significantly altered levels of metabolites related to citric acid cycle, purine, and pyrimidine metabolites compared to patients without cardiotoxicity. Here, ERBB2 is linked to breast cancer.